American Journal of Preventive Medicine
Volume 38, Issue 1 , Pages 47-53, January 2010

Use of Antithrombotic Agents Among U.S. Stroke Survivors, 2000–2006

  • Eric M. Cheng, MD, MS

      Affiliations

    • Department of Neurology, Health Services Research Program, David Geffen School of Medicine, University of California, Los Angeles, California
    • Department of Neurology, VA Greater Los Angeles Healthcare System, Los Angeles, California
    • HSR&D Center of Excellence, VA Greater Los Angeles Healthcare System, Sepulveda, California
    • Corresponding Author InformationAddress correspondence and reprint requests to: Eric M. Cheng, MD, MS, VA Greater Los Angeles Healthcare System, Department of Neurology, 11301 Wilshire Boulevard, Building 500, ML 127, Los Angeles CA 90073
  • ,
  • Stanley N. Cohen, MD

      Affiliations

    • Stroke Prevention Program, Nevada Neurosciences Institute at Sunrise, Las Vegas, Nevada
  • ,
  • Martin L. Lee, PhD

      Affiliations

    • Department of Biostatistics, UCLA School of Public Health, Los Angeles, California
    • HSR&D Center of Excellence, VA Greater Los Angeles Healthcare System, Sepulveda, California
  • ,
  • Stefanie D. Vassar, MS

      Affiliations

    • Department of Neurology, Health Services Research Program, David Geffen School of Medicine, University of California, Los Angeles, California
    • Department of Neurology, VA Greater Los Angeles Healthcare System, Los Angeles, California
  • ,
  • Alex Y. Chen, MD, MS

      Affiliations

    • Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California

Background

Secondary stroke prevention guidelines recommend antithrombotic agents such as over-the-counter aspirin, prescription antiplatelet agents, or anticoagulant agents.

Purpose

The study was designed to measure whether use of outpatient antithrombotic agents is increasing among stroke survivors.

Methods

The sample consisted of 4168 people who self-reported cerebrovascular disease and who participated in the Medical Expenditure Panel Survey, an annual representative sample of the U.S., during the years 2000–2006. Use of antithrombotic agents was calculated from face-to-face interviews about the use of aspirin and from pharmacies about the use of prescription medications. Cochran–Armitage tests were used to detect temporal trends and multivariate models to identify predictors of use of antithrombotic agents.

Results

Pooling results across the 7 years, it was found that 57% were taking aspirin, 66% were using any antiplatelet agent, and 75% were using any antithrombotic agent. After excluding people who said aspirin was unsafe, 81% were using any antithrombotic agent. During the study period, use of prescription antiplatelet agents increased (p<0.001) but there was no temporal change in use of antithrombotic agents overall. In multivariate models, being aged >65 years, male gender, non-Hispanic ethnicity, having a usual source of care, and poor or fair health status were associated with use of an antithrombotic agent (p<0.05).

Conclusions

Although a high percentage of stroke survivors appear to use an antithrombotic agent, further research should investigate whether and how to improve care among the remaining 20% of stroke survivors, particularly among younger, female, and Hispanic patients.

 

PII: S0749-3797(09)00633-3

doi:10.1016/j.amepre.2009.08.029

American Journal of Preventive Medicine
Volume 38, Issue 1 , Pages 47-53, January 2010